Secretech, Inc.

Basic Information

1025 18th Street South
Birmingham, AL, 35205

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS

    Amount: $438,684.00

    THE PURPOSE OF THE PHASE I STUDY IS TO EXPLORE A NOVEL APPROACH FOR INFLUENZA VIRUS VACCINATION BY USING MICROENCAPSULATED ANTIGENS ADMINISTERED BY THE ORAL OR INTRANASAL ROUTE IN ORDER TO INDUCE A PR ...

    SBIR Phase II 1993 Department of Health and Human Services
  2. Novel Adjuvant to Enhance Immunity Against PIV3

    Amount: $50,000.00

    We will apply a novel adjuvant to the production of an effective, safe vaccine against PIV3. The proposed adjuvant is a proprietary formulation of microcrystalline cellulose, starch, and sugar. We wil ...

    SBIR Phase I 1993 Department of Health and Human Services
  3. CTB as an Oral Adjuvant for Parainfluenza Vaccine

    Amount: $48,156.00

    The long term objective is to develop a commercial trivalent glycoprotein subunit vaccine for parainfluenza viruses. Because of the high cost of preparing these glycoproteins, a means for achieving an ...

    SBIR Phase I 1993 Department of Health and Human Services
  4. Microencapsulated Respiratory Syncytial Virus Vaccine

    Amount: $50,000.00

    The long term objective is to develop a commercial subunit vaccine for human respiratory syncytial virus (RSV). Because of the high cost of preparing these glycoproteins, a means for achieving an enha ...

    SBIR Phase I 1993 Department of Health and Human Services
  5. Mucosal Immunity Against Non-infectious SIV Particles

    Amount: $49,999.00

    The long term objective is to induce a protective mucosal immune response to prevent HIV-1 infection. We will immunize orally with recombinant defective SIV-like particles entrapped in microcapsules o ...

    SBIR Phase I 1993 Department of Health and Human Services
  6. Mucosal Vaccine for Sexually Transmitted Chlamydia

    Amount: $50,000.00

    The long term objective is to develop a commercial vaccine for the prophylactic treatment of sexually transmitted Chlamydia trachomatis. Parenteral or oral delivery of free antigen does not protect ag ...

    SBIR Phase I 1993 Department of Health and Human Services
  7. Microencapsulated Measles Virus Vaccine

    Amount: $50,000.00

    The long term objective is to develop a commercial subunit vaccine against MV infection. Because of the high cost of preparing the surface antigens, a means for achieving an enhanced immune response i ...

    SBIR Phase I 1993 Department of Health and Human Services
  8. VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES

    Amount: $290,133.00

    THE LONG-TERM OBJECTIVE OF THIS STUDY IS THE DEVELOPMENT OF AN EFFECTIVE DELIVERY SYSTEM FOR A LIVE HUMAN ROTAVIRUS VACCINE. TO AVOID THE INACTIVATION OF VIRUS BY GASTRIC ACID, DIFFERENT BUFFERS ARE B ...

    SBIR Phase II 1992 Department of Health and Human Services
  9. HUMAN PARAINFLUENZA TYPE 2 VIRUS GLYCOPROTEIN GENES

    Amount: $499,576.00

    IT IS PLANNED TO CONSTRUCT A CDNA LIBRARY OF HUMAN PARAINFLUENZA TYPE 2 VIRUS MRNA'S INTO A PLASMID VECTOR. THE LIBRARY WILL BE SCREENED BY COLONY HYBRIDIZATION. THE GENES ENCODING ENVELOPE GLYCOPROTE ...

    SBIR Phase II 1991 Department of Health and Human Services
  10. NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS

    Amount: $50,000.00

    N/A

    SBIR Phase I 1991 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government